These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29164480)

  • 1. Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia.
    Skelly A; Carius HJ; Bezlyak V; Chen FK
    Adv Ther; 2017 Dec; 34(12):2585-2600. PubMed ID: 29164480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
    Ferreira A; Sagkriotis A; Olson M; Lu J; Makin C; Milnes F
    PLoS One; 2015; 10(7):e0133968. PubMed ID: 26208030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration.
    Johnston SS; Wilson K; Huang A; Smith D; Varker H; Turpcu A
    Adv Ther; 2013 Dec; 30(12):1111-27. PubMed ID: 24310208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
    Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
    Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS; Muecke J
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I; Gianniou C; Dirani A
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.
    Lotery A; Griner R; Ferreira A; Milnes F; Dugel P
    Eye (Lond); 2017 Dec; 31(12):1697-1706. PubMed ID: 28731052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
    Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
    J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis.
    Böhni SC; Bittner M; Howell JP; Bachmann LM; Faes L; Schmid MK
    BMC Ophthalmol; 2015 Aug; 15():109. PubMed ID: 26289356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis.
    Danyliv A; Glanville J; McCool R; Ferreira A; Skelly A; Jacob RP
    Adv Ther; 2017 Mar; 34(3):611-619. PubMed ID: 28188433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial utilization of aflibercept in exudative age-related macular degeneration.
    Cho H; Weber ML; Shah CP; Heier JS
    Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
    Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.